Instrument NameNovo Nordisk A/S ADRInstrument Symbol(NVO-N)

Instrument ExchangeNYSE

One Wall Street analysts recently singled out a drug from pharma company Roche as a threat to Eli Lilly's oral GLP-1 candidate.

Paul Harris of Harris Douglas Asset Management says he hasn’t sold a stock since 2020. ‘I don’t feel the need to sell anything’

These are two of healthcare's biggest darlings right now, but one looks better positioned for the long run.

These stocks look like slam-dunk picks for growth investors.

Eli Lilly is the most valuable pharmaceutical company in the world. I believe the company has what it takes to stay there.

These two pharmaceutical giants are positioned for growth with their innovative diabetes and obesity treatments.

These stocks are all down 14% or more in the past three months.

Skye Bioscience has incredible potential upside, according to Wall Street analysts. It is striving to make a new weight loss drug, that could work with GLP-1s.

A victory for the current vice president on Nov. 5 may be bad news for three market-leading businesses.

Eli Lilly shares have soared thanks to excitement about the company's position in the weight loss drug market.

Shares of Ozempic-maker Novo Nordisk (NYSE:NVO) have been nosediving in recent weeks. And in the past ...

These companies have been on fire for a while, but they haven't peaked yet.

Check out these three micro-cap companies that have a big opportunity to succeed, but also significant a risk of failure.

Check out these three stocks each up over 60% in the past twelve months. Their strong paths for growth can help keep their momentum stories going.

NetworkNewsWire Editorial Coverage : Alzheimer’s disease (“AD”) has become a focal point in the pharmaceutical industry as recent drugs such as Leqembi and Kisunla have received U.S. Food and Drug Administration (“FDA”) approval. However, while...

Down 43% from all-time highs, Structure Therapeutics is a pre-revenue clinical-stage biopharma company that trades at a massive discount to consensus price target estimates.

These two players are set on finding the next big therapeutic modality.

The thrust of the company's long-term strategy is becoming clearer.

Even the mighty Novo Nordisk can't hold a candle to its peer in this area.

The healthcare company's pivot into a new set of technologies will have many implications for the stock.